StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.95−0.10 (-9.87%)

Close on Nov 16, 2026Market cap $26.27MP/E –Yield –

Inmune Bio operating margin

Operating margin is operating income as a percentage of revenue.

Inmune Bio's operating margin for the twelve months ending Dec 31, 2025 was -94766.0%. For fiscal 2025 it was -94766.0%, against -304535.7% the year before. The highest annual figure on record is -6938.8% in fiscal 2022.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-94766.0%+209769.7
FY2024Dec 31, 2024-304535.7%−285348.0
FY2023Dec 31, 2023-19187.7%−12249.0
FY2022Dec 31, 2022-6938.8%+9167.9
FY2021Dec 31, 2021-16106.6%+95057.0
FY2020Dec 31, 2020-111163.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2025Mar 31, 2025-19810.0%−5873.0
Q1 FY2024Mar 31, 2024-78692.9%−61790.2
Q4 FY2023Dec 31, 2023-29925.0%−24108.5
Q3 FY2023Sep 30, 2023-19832.6%−12237.7
Q2 FY2023Jun 30, 2023-13937.0%+25988.0
Q1 FY2023Mar 31, 2023-16902.6%−12928.4
Q4 FY2022Dec 31, 2022-5816.5%−276.6
Q3 FY2022Sep 30, 2022-7594.9%+56840.8
Q2 FY2022Jun 30, 2022-39925.0%+73775.0
Q1 FY2022Mar 31, 2022-3974.2%–
Q4 FY2021Dec 31, 2021-5539.9%–
Q3 FY2021Sep 30, 2021-64435.7%–
Q1 FY2021Mar 31, 2021-113700.0%–

More Inmune Bio figures

See a number that looks wrong?